SUMMARY In a double blind, single observer, 48 week study the effects of sulphasalazine (2 g daily) and hydroxychloroquine (400 mg daily months 0-6, thereafter 200 mg daily) were compared in 60 patients with definite or classical rheumatoid arthritis. They had not been treated previously with second line drugs. The onset of response with sulphasalazine was earlier than with hydroxychloroquine. After 48 weeks a comparison of the treatments showed no statistically significant differences in disease activity variables. Adverse reaction was the main reason for withdrawal in the sulphasalazine group and lack of efficacy in the hydroxychloroquine group. All adverse reactions, one being agranulocytosis after eight weeks of sulphasalazine treatment, appeared in the first three months of treatment and were completely reversible. In these studies the efficacy of sulphasalazine proved to be similar to that of D-penicillamine and somewhat less than that of aurothiomalate. In
January 1985 we started a double blind trial to compare sulphasalazine with hydroxychloroquine. The latter drug is a disease modifying drug of first choice for rheumatoid arthritis in a number of European countries. No comparisons of hydroxychloroquine and sulphasalazine have been published so far.
Patients and methods
Patients from five participating clinics were included in the study. All patients were seen by one observer. Sixty patients with definite or classical rheumatoid arthritis according to American Rheumatism Association criteria,1' disease onset after age 16 , and between 18 and 75 years old entered the study. Patients with serious complicating illnesses or previous reactions to sulphonamides or salicylates were excluded. Also excluded were patients of both sexes with a desire for children and patients previously treated with other second line drugs. Corticosteroid treatment was not permitted for three months before and during the trial. All patients had active disease, which was not adequately controlled by non-steroidal anti-inflammatory drugs. Active disease was characterised by at least three of the following five criteria: seven or more joints painful or tender at motion; four or more swollen joints; 389 morning stiffness lasting for at least one hour; Westergren erythrocyte sedimentation rate exceeding 28 mm/lst h; and anaemia (haemoglobin -138 g/l in men, <118 g/l in women).
DRUG ADMINISTRATION
Concomitant treatment with non-steroidal antiinflammatory drugs in a stable dose for one month before entry was continued throughout the study as far as possible; no other concomitant drug treatment for rheumatoid arthritis was allowed, neither were intra-articular steroid injections. Double blinding was accomplished by a double dummy technique. Patients receiving hydroxychloroquine took 200 mg twice a day for the first six months, thereafter 200 mg once daily, according to the standard scheme. Patients receiving sulphasalazine took an initial dose of 500 mg/day. At four-day intervals this was increased by 500 mg to a maximum dose of 2 g/day.
STUDY DESIGN
The study was a 48 week parallel, double blind trial of hydroxychloroquine versus sulphasalazine. The patients entered the study over a period of 18 months and were allocated to receive either sulphasalazine or hydroxychloroquine using a blocked randomisation procedure. The patients were followed up at the outpatient clinic and were all seen by the same observer (IHNZ). The All patients were checked in the event of visual complaints; the patients receiving hydroxychloroquine were checked at least after one year.
ADVERSE REACTIONS
At each visit the patients were questioned about new symptoms. The relation between the trial drug treatment and any new symptom was discussed.
COMPLIANCE
Return drug count was used to measure patient compliance.
STATISTICAL ANALYSIS
The comparison of treatment groups at baseline was by t test for continuous variables and x2 test for categorical variables. For patients withdrawn before the end of the planned treatment period the last observed value was used in the statistical analysis (end point analysis).14 In each patient the change from baseline was calculated as the score after treatment minus the baseline score. These changes were compared between treatment groups using a two sample t test. The changes within the groups were statistically tested using a paired t test. p Values <0-05 were considered significant. Thirty patients in each treatment group permits with 95% confidence the detection of a difference between two means of about one standard deviation.
Results
Sixty patients entered the study. At the start of the study the differences between the sulphasalazine and hydroxychloroquine treatment groups were not statistically significant either in clinical characteristics (Table 1 ) or in disease activity (Table 2) .
Three patients withdrawn within the first month (two because of protocol violation and one because of vomiting) were excluded from the analysis of efficacy. All 60 patients were included in the analysis of safety.
RESPONSE BY TREATMENT GROUP
In the sulphasalazine treated group improvement from baseline reached statistical significance after four weeks for the duration of morning stiffness, grip strength, pain score, IgM, and IgG; after eight Table 3 gives the number of patients, type of adverse reaction, the time of observation, and the number and reasons for withdrawals. All adverse reactions in both treatment groups were observed in the first three months of treatment.
In the sulphasalazine group there were nine withdrawals. Of these, two were for non-drugrelated reasons, three because of lack of effect, and four due to adverse reactions. The most severe adverse reaction was agranulocytosis after eight Haemoglobin (g/l)
129 (16) 126 (14) 126 (14) 130 (14) 127 (15) 130 (14) IgA (g/l) 
Discussion
We compared the efficacy and toxicity of sulphasalazine and hydroxychloroquine in the treatment of patients with active rheumatoid arthritis not previously treated with disease modifying drugs. Both drugs have been shown in earlier placebo controlled studies to have a disease modifying effect.6 7 [15] [16] [17] [18] We are aware that the dose reduction of hydroxychloroquine after six months in the study might have influenced the results. We felt justified in doing this, however, because it is a widely accepted practice in order to lower the toxicity rate, especially ocular toxicity. '9 We found that treatment with sulphasalazine apparently has some advantages over the use of hydroxychloroquine, notably the quicker response. Within the sulphasalazine group significant improvement from baseline was recorded for duration of morning stiffness, grip strength, and pain score after only four weeks of treatment. This was followed by significant improvement in erythrocyte sedimentation rate and C reactive protein (week 8), Ritchie articular index and number of swollen joints (week 12), and, finally, number of tender joints (week 20) and general health (week 24). In the hydroxychloroquine group a significant change from baseline was not found until week 12-namely, for number of swollen joints. Later on, Ritchie articular index and duration of morning stiffness (week 16), pain score (week 20), erythrocyte sedimentation rate (week 24), and number of tender joints (week 28) improved. This group showed no significant improvement in grip strength and improvement only in week 20 for C reactive protein. It therefore appears that the onset of response in the sulphasalazine group was about eight weeks earlier than that in the hydroxychloroquine group. A similar early response to treatment with sulphasalazine has been noted by other investigators.7 9 Our data also indicate that the response to treatment was better in the sulphasalazine group than in the hydroxychloroquine group as 11 disease activity parameters improved during sulphasalazine treatment as compared with only four in the hydroxychloroquine group. Furthermore, at some times during the study there were significant differences between thegroups for several parameters. Finally, the number dropping out owing to lack of effect was nine in the hydroxychloroquine group and three in the sulphasalazine group. This difference was not significant (Fisher's exact test p=01041) .
On the other hand, there were more side effects and more patients withdrawing owing to toxicity in the sulphasalazine group than in the hydroxychloroquine group. In the hydroxychloroquine group adverse reactions were found in 7/30 (23%) of the patients. Most frequently we observed gastrointestinal side effects (4/30; 13%). Retinopathy, the most serious toxic effect of hydroxychloroquine treatment,20 did not occur in our patients. All adverse reactions were mild and reversible. Only one patient dropped out in this group. In the sulphasalazine group 9/30 (30%) of the patients had side effects, all of them reversible and none of a kind that has not been reported in previous studies.°-10 Nausea and vomiting was the most frequent side effect present in 6/30 (20%) of the patients at some point, mostly early in the study. The percentage of adverse reactions, particularly gastrointestinal toxicities, is probably dose dependent. In studies using a dose of 3 g daily6 7 the percentage of side effects was reportedly higher than in those with a daily dose of 2 g,5 8 Al, A3, B7, B8, DR3, and DR4. Interestingly, the patient with agranulocytosis also possessed the HLA-B7 phenotype. Further studies are currently in progress to investigate the possibility that the development of sulphasalazine induced leucopenia is genetically determined. Eight cases of leucopenia were reported by Amos et al in a study of 774 patients treated with sulphasalazine.24 Again, the leucopenia was reversible and occurred in the first three months of treatment in all cases. In our study four (13%) of 30 patients in the sulphasalazine group withdrew owing to toxicity, a percentage comparable with that in other studies using 2 g daily5 8 and lower than that in studies with a daily dose of 3 g (30%).
We conclude from our data that sulphasalazine induces an earlier and slightly better response than hydroxychloroquine. The earlier response to sulphasalazine, especially, may be an important advantage in terms of quality of life for patients with rheumatoid arthritis as other disease modifying drugs, such as D-penicillamine and gold compounds, are generally effective only after three to four months. Recent studies have shown that sulphasalazine has the same efficacy as D-penicillamine 9 10 and is only slightly less effective than aurothiomalate.6 8 With a daily dose of 2 g sulphasalazine the withdrawal rate due to adverse reactions is lower than that with aurothiomalate and D-penicillamine. Adverse reactions, including leucopenia, are mainly observed in the first three months of treatment. Therefore our policy is to check blood counts once a fortnight for the first three months, thereafter every four to eight weeks. Furthermore, patients are instructed to contact us if they develop a fever. 
